Huahai Pharmaceutical secures approval for Canagliflozin Tablets

Zhejiang Huahai Pharmaceutical Company Limited announced it has obtained a drug registration certificate from the National Medical Products Administration for its Canagliflozin Tablets. The 100mg tablet is classified as a chemical drug category 4 for domestic production.

Canagliflozin Tablets are indicated for improving blood glucose control in adults with type 2 diabetes, both as an add-on to metformin when metformin alone is insufficient, and in combination with metformin and sulfonylureas. The original drug was developed by Janssen and first launched in the U.S. in March 2013, with domestic approval in China in September 2017.

The company invested approximately RMB 5.64 million in the research and development of Canagliflozin Tablets. This approval is expected to enrich the company's product line and enhance its market competitiveness, allowing for priority procurement by medical institutions and clinical use. According to projections from Menet.com, the domestic market sales of Canagliflozin Tablets are estimated to reach approximately RMB 370 million in 2024.